Bio-Rad Laboratories (BIO) Free Cash Flow Growth (1y) (2010 - 2026)
Bio-Rad Laboratories (BIO) Free Cash Flow Growth (1y) (2010 - 2026) Analysis & Trends
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.63 Bn | 194.02 Bn | 7.27 Bn | 28.87% |
| 2 | Stryker | 127.42 Bn | 123.95 Bn | 4.50 Bn | 14.12% |
| 3 | Medtronic | 118.97 Bn | 109.75 Bn | 6.41 Bn | 0.77% |
| 4 | Boston Scientific | 73.39 Bn | 72.85 Bn | 3.85 Bn | 13.29% |
| 5 | Edwards Lifesciences | 51.97 Bn | 47.72 Bn | 1.35 Bn | 142.84% |
| 6 | Dexcom | 34.32 Bn | 32.37 Bn | 830.00 Mn | -11.68% |
| 7 | GE HealthCare Technologies | 33.76 Bn | 31.65 Bn | 2.18 Bn | 750.00% |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn | 0.40% |
| 9 | Steris | 23.04 Bn | 22.56 Bn | 684.20 Mn | -14.34% |
| 10 | Bio-Rad Laboratories | 10.11 Bn | 8.49 Bn | 345.80 Mn | -5.79% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.79% |
| Mar 31, 2026 | -18.22% |
| Dec 31, 2025 | 46.49% |
| Sep 30, 2025 | -27.71% |
| Jun 30, 2025 | 28.03% |
| Mar 31, 2025 | 222.64% |
| Dec 31, 2024 | 109.87% |
| Sep 30, 2024 | 130.12% |
| Jun 30, 2024 | -12.83% |
| Mar 31, 2024 | -52.56% |
| Dec 31, 2023 | -13.52% |
| Sep 30, 2023 | 423.33% |
| Jun 30, 2023 | 76.36% |
| Mar 31, 2023 | 258.26% |
| Dec 31, 2022 | -60.95% |
| Sep 30, 2022 | -108.47% |
| Jun 30, 2022 | -72.59% |
| Mar 31, 2022 | -81.48% |
| Dec 31, 2021 | -53.27% |
| Sep 30, 2021 | 69.14% |